April 11, 2018 10:15 AM EDT

Flush with a $164M raise, Cellectis ups its bet on CAR-T and gene editing programs

Amber Tong

With new partners at Allogene Therapeutics, Cellectis $CLLS is ready to hustle its off-the-shelf CAR-T therapies to the market — taking advantage of $164 million it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Flush with a $164M raise, Cellectis ups its bet on CAR-T and gene editing programs

Amber Tong

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Flush with a $164M raise, Cel­lec­tis ups its bet on CAR-T and gene edit­ing pro­grams

Amber Tong

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Flush with a $164M raise, Cellectis ups its bet on CAR-T and gene editing programs

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA